Overview

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Status:
Recruiting
Trial end date:
2023-07-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Phase:
Phase 3
Details
Lead Sponsor:
Allergan